A breast cancer PDX collection enriched in luminal ( ER + ) tumors and young premenopausal patients to identify new therapeutic strategies for high‐risk patients †
The Journal of Pathology · 2025
DOI: 10.1002/path.6418 ↗Kurz gefasst
Kommentar in der Zeitschrift The Journal of Pathology, 2025. Verfasst von Paola Defilippi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Breast Neoplasms, Receptors, Estrogen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Fondazione AIRC per la ricerca sul cancro ETS.
Abstract (Originalsprache)
Breast cancer includes a group of neoplasms originating from mammary gland epithelial cells caused by a variety of genetic alterations, with different responses to treatments and outcomes. In clinical practice, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression guides the distinction between luminal A (ER + , PR + , HER2 − ), luminal B (ER + , PR + , HER2 +/− ), and triple‐negative (ER − , PR − , HER2 − ), each with a distinct biological behavior and clinical and therapeutic implications. Approximately 11% of breast cancers are diagnosed in young premenopausal women aged 20–49 years. Patient‐derived xenografts (PDXs) offer a powerful solution to integrate personalized medicine and novel therapeutic agents. Dr Belletti's group recently developed a PDX biobank composed of 26 PDX lines highly enriched in luminal A and B and young premenopausal breast cancer patients. The bank faithfully recapitulates the characteristics of the original tumors. A major focus of their research was to exploit these PDXs to assess the resistance to CDK4/6 inhibitors (CDK4/6i), which are critical in managing advanced luminal breast cancers. Their effort addresses a significant gap in existing PDX models, which are limited for these patient subgroups, thereby enabling deeper insights into tumor biology and therapeutic responses in these understudied populations. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
- UCL, Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London, UK.
ORCID-Profile: Paola Defilippi
Förderung
- Associazione Italiana per la Ricerca sul Cancro
- Fondazione AIRC per la ricerca sul cancro ETS
Zitieren
APA
Defilippi, P., Nigrelli, F., Arina, P., Taverna, D., & Salemme, V. (2025). A breast cancer PDX collection enriched in luminal ( ER + ) tumors and young premenopausal patients to identify new therapeutic strategies for high‐risk patients †. The Journal of Pathology. https://doi.org/10.1002/path.6418
Vancouver
Defilippi P, Nigrelli F, Arina P, Taverna D, Salemme V. A breast cancer PDX collection enriched in luminal ( ER + ) tumors and young premenopausal patients to identify new therapeutic strategies for high‐risk patients †. The Journal of Pathology. 2025. doi:10.1002/path.6418
BibTeX
@article{Defilippi2025,
author = {Defilippi, Paola and Nigrelli, Francesca and Arina, Pietro and Taverna, Daniela and Salemme, Vincenzo},
title = {A breast cancer PDX collection enriched in luminal ( ER + ) tumors and young premenopausal patients to identify new therapeutic strategies for high‐risk patients †},
journal = {The Journal of Pathology},
year = {2025},
doi = {10.1002/path.6418}
}
EUVIMED